UroGen Pharma 2024年第四季度GAAP每股收益$(0.80) 未达$(0.68)预期,销售额$24.57M 未达$25.63M预期

财报速递2025-03-10
UroGen Pharma (NASDAQ:URGN) 报告季度每股亏损$(0.80),比分析师一致预期的$(0.68)低17.65%。这是相比去年同期每股亏损$(0.72)下降了11.11%。公司报告季度销售额为$24.57百万,比分析师一致预期的$25.63百万低4.17%。与去年同期销售额$23.53百万相比,这是增长了4.40%。

以上内容来自Benzinga Earnings专栏,原文如下:

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.68) by 17.65 percent. This is a 11.11 percent decrease over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $24.57 million which missed the analyst consensus estimate of $25.63 million by 4.17 percent. This is a 4.40 percent increase over sales of $23.53 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法